PHARMORIS WORKFLOW SESSION
Map one stalled medicines workflow.
Bring one evidence bottleneck, ownership gap or implementation constraint. See how a representative PHARMORIS workflow could connect the source to a human decision, an ActionCase, delivery work and a reviewable result.
Representative · Synthetic or approved public material · Non productionWHAT YOU CAN LEAVE WITH
A clearer view of where the work stalls, and what would move it.
The useful outcome is not a tour of screens. It is a shared map of the evidence, decision, owner, blockers and review path around one medicines opportunity, plus a realistic view of whether PHARMORIS fits the problem.
The walkthrough uses representative material rather than live patient data, so the conversation can focus on workflow and operating value without asking you to expose sensitive information.
- 01
Locate the friction
Identify where evidence, authority, ownership or implementation currently becomes disconnected.
- 02
Map the decision chain
See which authorised roles need to triage, decide, coordinate, acknowledge or review.
- 03
Build the ActionCase
Explore how the source, owner, state, blockers, decisions and tasks could live in one governed record.
- 04
Define useful evidence
Separate the initial opportunity, decision basis, projected value and later observed evidence.
- 05
Choose the next question
Leave knowing what PHARMORIS could address, what needs further proof and what should not progress.
THE REPRESENTATIVE WALKTHROUGH
Follow the opportunity from signal to review.
A productive session follows one coherent thread rather than jumping between features. Start with the evidence that triggered the work and finish with the question the later ValueReview must be able to answer.
- 01
Source and CandidateSignal
Identify what triggered the opportunity, when it was received, what it can support and what remains unknown.
- 02
Human triage
See how an authorised person can accept, reject, defer or request more evidence before an ActionCase exists.
- 03
ActionCase and EvidencePack
Keep the working record, decision material, owner, blockers and version history connected but distinct.
- 04
Decision, delivery and ValueReview
Carry the human decision into coordinated work, preserve receiver responses and define the evidence needed for later review.
IF THE FIT IS REAL
Design the smallest evaluation that can answer a serious question.
The next step should not be a vague pilot. It should be a bounded evaluation with one intended use, named owners, permitted data, clear measures and a decision that can be taken when the evidence is reviewed.
- 01
One workflow
Choose a problem narrow enough to understand and important enough to matter.
- 02
One decision group
Identify the people who hold medicines, financial, operational and assurance authority for the scope.
- 03
One evidence plan
Define the sources, permissions, baseline, limitations and review method before activity starts.
- 04
One controlled environment
Agree the data class, access boundaries, configuration, testing and stop conditions appropriate to the evaluation.
- 05
One reviewable next decision
Know in advance what evidence would justify continuing, narrowing, redesigning or stopping.
PREPARE THE CONVERSATION
Bring the operating problem, not sensitive data.
You do not need to send patient identifiable or confidential information, credentials or other security sensitive material. A useful first description explains what happens today, where the work stalls, who decides and what a better outcome would look like.
Workflow
What happens today, and where does ownership or review become unclear?
Evidence
Which source or controlled reference begins the work, and what limitations must stay visible?
Authority
Who is authorised to triage, decide, approve, override and close the work?
Evaluation question
What evidence would your institution need before considering a further evaluation?
PHARMORIS demo
Request a focused product conversation.
Tell us about the workflow or institutional question you want to examine. Demonstrations remain representative and are not live.
No data that identifies patients
No confidential clinical records
Human response only
START WITH ONE REAL QUESTION
Make the next conversation earn the time it takes.
Tell us where a medicines opportunity currently gets stuck. We will use the product overview and current status to keep the session grounded in what PHARMORIS is actually being built to do.